Oscient Pharmaceuticals (OSCI) Misses Q1 EPS by 12c, Receives FDA Approval for FACTIVE Five-Day Treatment of Community-Acquired Pneumonia
More News related to OSCI
- Oscient Pharmaceuticals (OSCI) Files Chapter 11 Bankruptcy; Shares Deemed No Value
- Oscient Pharmaceuticals (OSCI) Discontinues Direct Selling of its Products; Eliminates 150-Person Sales Force
- Oscient Pharma (OSCI) Reports Smaller Q4 Loss
- Oscient Pharmaceuticals (OSCI) Cuts 32% of Workforce
- Oscient Pharmaceuticals (OSCI) Completes Convertible Exchange Offer; to Issue $85M in New 12.5% Convertible Senior Notes and 21M Shares of Common Stock
More News related to Earnings
- Charming Shoppes (CHRS) Reports Mixed Q3 Results
- Descartes Systems Group (DSGX) Posts In-Line Q1 EPS of 9c
- China BAK Battery (CBAK) Posts Q4 Loss of $0.02, Better by 1c
- Shanda Interactive (SNDA) Posts Q3 EPS of $0.90, Beats by 2c
- Jos. A Bank Clothiers (JOSB) Posts Q3 EPS of $0.63, Topes by 9c
Oscient Pharmaceuticals Corp. (Nasdaq: OSCI) reports a Q1 loss of $0.88, 12 cents worse than estimates. Revenues were $23.2 million vs. $23.09 million consensus.
Separately, The U.S. Food and Drug Administration (FDA) has approved Oscient Pharmaceuticals' FACTIVE tablets for the five-day treatment of community-acquired pneumonia of mild to moderate severity (CAP). The approved supplemental New Drug Application (sNDA) was based on the results of the Company's successful Phase III trial in 510 CAP patients comparing a five-day treatment and the originally approved seven-day treatment with FACTIVE 320 mg once-daily.
Related Categories
EarningsFDA
Stocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
